How to buy Aldeyra Therapeutics stock

Aldeyra Therapeutics, Inc is a biotechnology business based in the US. Aldeyra Therapeutics shares (ALDX) are listed on the NASDAQ and all prices are listed in US Dollars. Aldeyra Therapeutics employs 11 staff and has a market cap (total outstanding shares value) of 0.00.

Aldeyra Therapeutics share price

Use our graph to track the performance of ALDX stocks over time.

Aldeyra Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-28.

52-week range	$2.60 - $14.62
50-day moving average	$11.76
200-day moving average	$9.67
Wall St. target price	$25.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.00

Buy Aldeyra Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Aldeyra Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Aldeyra Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aldeyra Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-27.28%
Return on equity TTM	-69.81%
Profit margin	0%
Book value	$1.54
Market capitalisation	$662.3 million

TTM: trailing 12 months

Shorting Aldeyra Therapeutics shares

There are currently 4.7 million Aldeyra Therapeutics shares held short by investors – that's known as Aldeyra Therapeutics's "short interest". This figure is 2.3% down from 4.8 million last month.

There are a few different ways that this level of interest in shorting Aldeyra Therapeutics shares can be evaluated.

Aldeyra Therapeutics's "short interest ratio" (SIR)

Aldeyra Therapeutics's "short interest ratio" (SIR) is the quantity of Aldeyra Therapeutics shares currently shorted divided by the average quantity of Aldeyra Therapeutics shares traded daily (recently around 767224.9589491). Aldeyra Therapeutics's SIR currently stands at 6.09. In other words for every 100,000 Aldeyra Therapeutics shares traded daily on the market, roughly 6090 shares are currently held short.

However Aldeyra Therapeutics's short interest can also be evaluated against the total number of Aldeyra Therapeutics shares, or, against the total number of tradable Aldeyra Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aldeyra Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Aldeyra Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1229% of the tradable shares (for every 100,000 tradable Aldeyra Therapeutics shares, roughly 123 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Aldeyra Therapeutics.

Find out more about how you can short Aldeyra Therapeutics stock.

Aldeyra Therapeutics share dividends

We're not expecting Aldeyra Therapeutics to pay a dividend over the next 12 months.

Aldeyra Therapeutics share price volatility

Over the last 12 months, Aldeyra Therapeutics's shares have ranged in value from as little as $2.6 up to $14.6178. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aldeyra Therapeutics's is 1.7242. This would suggest that Aldeyra Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aldeyra Therapeutics overview

Aldeyra Therapeutics, Inc. , a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc.

Frequently asked questions

• What percentage of Aldeyra Therapeutics is owned by insiders or institutions?

  Currently 1.956% of Aldeyra Therapeutics shares are held by insiders and 55.748% by institutions.

• How many people work for Aldeyra Therapeutics?

  Latest data suggests 11 work at Aldeyra Therapeutics.

• When does the fiscal year end for Aldeyra Therapeutics?

  Aldeyra Therapeutics's fiscal year ends in December.

• Where is Aldeyra Therapeutics based?

  Aldeyra Therapeutics's address is: 131 Hartwell Avenue, Lexington, MA, United States, 02421

• What is Aldeyra Therapeutics's ISIN number?

  Aldeyra Therapeutics's international securities identification number is: US01438T1060

• What is Aldeyra Therapeutics's CUSIP number?

  Aldeyra Therapeutics's Committee on Uniform Securities Identification Procedures number is: 01438T106